![Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results | Business Wire Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results | Business Wire](https://mms.businesswire.com/media/20200723005170/en/305625/22/puma_logo_JPEG.jpg)
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results | Business Wire
![Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile](https://image1.owler.com/109906_1365481459487.png)
Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
![Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer](https://mms.businesswire.com/media/20191211005896/en/762417/4/Untitled-1.jpg)
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
![Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD](https://www.investors.com/wp-content/uploads/2017/11/Stock-biotech-09-adobe.jpg)
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
![EbeneInfo - AU - US $ 1033: This is what analysts think Puma Biotechnology, Inc (NASDAQ: PBYI) is worth after its latest results - EBENE INFO EbeneInfo - AU - US $ 1033: This is what analysts think Puma Biotechnology, Inc (NASDAQ: PBYI) is worth after its latest results - EBENE INFO](https://i1.wp.com/fr.ebeneinfo.com/wp-content/uploads/2020/11/4d522452d0da08d8412701a84270533b.jpeg?fit=1194%2C432&ssl=1&resize=350%2C200)